88 related articles for article (PubMed ID: 21146821)
1. Chromosome 9p21 and coronary risk--the mystery continues.
Linsel-Nitschke P; Schunkert H
Atherosclerosis; 2011 Feb; 214(2):257-8. PubMed ID: 21146821
[No Abstract] [Full Text] [Related]
2. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 9p21 and coronary artery disease.
McPherson R
N Engl J Med; 2010 May; 362(18):1736-7. PubMed ID: 20445187
[No Abstract] [Full Text] [Related]
4. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
5. Interferon-γ activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype.
Almontashiri NA; Fan M; Cheng BL; Chen HH; Roberts R; Stewart AF
J Am Coll Cardiol; 2013 Jan; 61(2):143-7. PubMed ID: 23199516
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 9p21 and cardiovascular disease: the story unfolds.
Samani NJ; Schunkert H
Circ Cardiovasc Genet; 2008 Dec; 1(2):81-4. PubMed ID: 20031549
[No Abstract] [Full Text] [Related]
7. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.
Conway C; Beswick S; Elliott F; Chang YM; Randerson-Moor J; Harland M; Affleck P; Marsden J; Sanders DS; Boon A; Knowles MA; Bishop DT; Newton-Bishop JA
Genes Chromosomes Cancer; 2010 May; 49(5):425-38. PubMed ID: 20140953
[TBL] [Abstract][Full Text] [Related]
8. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
[TBL] [Abstract][Full Text] [Related]
9. ANRIL: molecular mechanisms and implications in human health.
Congrains A; Kamide K; Ohishi M; Rakugi H
Int J Mol Sci; 2013 Jan; 14(1):1278-92. PubMed ID: 23306151
[TBL] [Abstract][Full Text] [Related]
10. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
[TBL] [Abstract][Full Text] [Related]
11. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma.
Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T
Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577
[TBL] [Abstract][Full Text] [Related]
12. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study.
Johnson AD; Hwang SJ; Voorman A; Morrison A; Peloso GM; Hsu YH; Thanassoulis G; Newton-Cheh C; Rogers IS; Hoffmann U; Freedman JE; Fox CS; Psaty BM; Boerwinkle E; Cupples LA; O'Donnell CJ
Circulation; 2013 Feb; 127(7):799-810. PubMed ID: 23315372
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
[TBL] [Abstract][Full Text] [Related]
14. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?
Hannou SA; Wouters K; Paumelle R; Staels B
Trends Endocrinol Metab; 2015 Apr; 26(4):176-84. PubMed ID: 25744911
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma.
Peters G
J Natl Cancer Inst; 2008 Jun; 100(11):757-9. PubMed ID: 18505965
[No Abstract] [Full Text] [Related]
16. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.
Harismendy O; Notani D; Song X; Rahim NG; Tanasa B; Heintzman N; Ren B; Fu XD; Topol EJ; Rosenfeld MG; Frazer KA
Nature; 2011 Feb; 470(7333):264-8. PubMed ID: 21307941
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
[TBL] [Abstract][Full Text] [Related]
18. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
[TBL] [Abstract][Full Text] [Related]
19. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
[TBL] [Abstract][Full Text] [Related]
20. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
